Creative Medical Technology Holdings (CELZ) Assets Average (2011 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Assets Average of $7.1 million for Q1 2026, down 5.1% year-over-year from $7.5 million in Q1 2025, and up 4.3% quarter-over-quarter from $6.8 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Assets Average (2011 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Assets Average for 16 consecutive years, with $7.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 5.1% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (down 5.1% YoY), while the FY2025 annual figure was $7.2 million, down 16.71% from the prior year.
- Assets Average improved to $7.1 million in Q1 2026 per CELZ's latest filing, from $6.8 million in the prior quarter.
- Across five years, Assets Average topped out at $23.0 million in Q3 2022 and bottomed at $6.5 million in Q3 2025.
- Historically, Assets Average has averaged $11.6 million across 5 years, with a median of $10.2 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average surged 1967.6% — and 2023, when it tumbled 44.23%.
- Creative Medical Technology Holdings' Assets Average stood at $20.8 million in 2022, then sank by 44.23% to $11.6 million in 2023, then sank by 41.64% to $6.8 million in 2024, then increased by 0.78% to $6.8 million in 2025, then grew by 4.3% to $7.1 million in 2026.
- Business Quant data shows CELZ's Assets Average at $7.1 million in Q1 2026, $6.8 million in Q4 2025, and $6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | 7.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.91 Mn |
| Mar 31, 2026 | 7.13 Mn |
| Dec 31, 2025 | 6.83 Mn |
| Sep 30, 2025 | 6.48 Mn |
| Jun 30, 2025 | 7.73 Mn |
| Mar 31, 2025 | 7.51 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | 7.44 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Mar 31, 2024 | 10.17 Mn |
| Dec 31, 2023 | 11.61 Mn |
| Sep 30, 2023 | 13.32 Mn |
| Jun 30, 2023 | 14.68 Mn |
| Mar 31, 2023 | 17.21 Mn |
| Dec 31, 2022 | 20.83 Mn |
| Sep 30, 2022 | 22.95 Mn |
| Jun 30, 2022 | 16.58 Mn |
| Mar 31, 2022 | 10.50 Mn |
| Dec 31, 2021 | 7.20 Mn |
| Sep 30, 2021 | 1.93 Mn |